NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.
Nanoliposomal Irinotecan|Cadonilimab|Oxaliplatin|Capecitabine|First-Line|Advanced Cancer|Pancreatic Adenocarcinoma|Drug Use
DRUG: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
Objective Response Rate (ORR), ORR of regimen of NALIRI-XELOX+AK104, 2 years
Duration of Response (DoR), 2 years|Disease Control Rate (DCR), 2 years|Median Progression-Free Survival (mPFS), 1 years|12-month PFS rate, 12 months|Median Overall Survival (mOS), 2 years|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Adverse Events (AEs) Incidence, Serious Adverse Events (SAE) Incidence, 2 years
This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.